US 2013/0095109 A1Published application

Antibody polypeptides that antagonize cd40l

AssigneesDomantis Limited, Bristol-Myers Squibb Company

InventorsSteven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Claims41

Dependent claims

An isolated antibody polypeptide comprising a first variable domain that specifically binds human CD40L, wherein CD40L comprises the amino acid sequence of SEQ ID NO:

1, wherein the amino acid sequence of the first variable domain comprises
(a) a CDR1 region which differs from the CDR1 region of BMS2h-572-633 by up to three amino acids,
(b) a CDR2 region which differs from the CDR2 region of BMS2h-572-633 by up to three amino acids,
(c) a CDR3 region which differs from the CDR3 region of BMS2h-572-633 by up to three amino acids,
(d) a FR1 region which differs from the FR1 region of BMS2h-572-633 by up to three amino acids,
(e) a FR2 region which differs from the FR2 region of BMS2h-572-633 by up to three amino acids,
(f) a FR3 region which differs from the FR3 region of BMS2h-572-633 by up to three amino acids, and
(g) a FR4 region which differs from the FR4 region of BMS2h-572-633 by up to three amino acids;
and
wherein the antibody polypeptide inhibits binding of CD40L to CD40 with an EC50 of 100 pM to 100 nM.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application: 13/650,493Filed 12 Oct 2012
Priority: 13 Oct 2011
Published: 18 Apr 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification62 codes

C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…